Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study-Reference-Cited by-同舟云学术

Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study

Published:2010-05 Issue:5 Volume:11 Page:459-464
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Ree Anne Hansen,Dueland Svein,Folkvord Sigurd,Hole Knut H,Seierstad Therese,Johansen Marianne,Abrahamsen Torveig W,Flatmark Kjersti

Publisher

Elsevier BV

Subject

Oncology

Reference21 articles.

1. Cell-cycle checkpoints and cancer;Kastan;Nature,2004

2. Targeting the DNA damage response in cancer;Ljungman;Chem Rev,2009

3. Molecular targets for tumor radiosensitization;Tofilon;Chem Rev,2009

4. Novel targeted radiosensitisers in cancer treatment;Zaidi;Curr Drug Discov Technol,2009

5. Anti-cancer activities of histone deacetylase inhibitors;Bolden;Nat Rev Drug Discov,2006

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Epigenetic Mechanisms in the Treatment of GI Cancers;Current Cancer Drug Targets;2024-06-28

2. Stochasticity of anticancer mechanisms underlying clinical effectiveness of vorinostat;Heliyon;2024-06

3. Role of p53, Cancer Stem Cells, and Cellular Senescence in Radiation Response;International Journal of Biomedicine;2023-09-05

4. HDAC-an important target for improving tumor radiotherapy resistance;Frontiers in Oncology;2023-07-12

5. Intestinal organoids: A versatile platform for modeling gastrointestinal diseases and monitoring epigenetic alterations;Life Sciences;2023-04